Increased Vancomycin Clearance in Patients with Solid Malignancies

• Published in: Biological and Pharmaceutical Bulletin 2020-07, Vol.43 (7), p.1081-1087
• Main Authors: Tomohiro Izumisawaa, b, Nobuyuki Wakuic, Tomoyoshi Kanekob, Masakazu Somab, Masahiko Imaia, Daisuke Saitoa, Hideo Hasegawab, Tetsuya Horinod, Noriko Takahashia
• Format: Article
• Language: Japanese
• ISSN: 0918-6158

Vancomycin (VAN) is an anti-microbial agent used to treat a number of bacterial infections, which has a high incidence of nephrotoxicity. We examined the pharmacokinetics of VAN retrospectively based on trough concentrations at large scale and identified pharmacokinetic differences between Japanese patients having solid malignancy and non-malignancy patients. Data were analyzed from 162 solid malignancy patients and 261 non-malignancy patients, including the patient's background, VAN dose, and pharmacokinetics of VAN. We failed to detect differences in values for VAN clearance or shorter elimination half-lives between these two groups. In contrast, multiple regression analysis under adjusting for confounding factors by propensity score, showed that VAN clearance significantly increased in relation to solid malignancies in each stage. We conclude that VAN clearance in solid malignancy patients is increased and that the blood concentration of VAN becomes lower than expected. These results suggest that early monitoring of VAN levels in solid malignancy patients might be essential for maintaining desired effects without side-effects.